Have a personal or library account? Click to login
Experience of switching to NovoEight: views of people with haemophilia Cover

Experience of switching to NovoEight: views of people with haemophilia

The Journal of Haemophilia Practice
Volume 7 (2020): Issue 1 (January 2020)
By: Debra Pollard,  Kate Khair and  Mike Holland  
Open Access
|Jun 2020

Figures & Tables

A survey of people with haemophilia in the UK whose factor product was switched to NovoEight found that although most felt they had little influence on the decision to switch, the majority continued to have confidence in the new treatment© Shutterstock
A survey of people with haemophilia in the UK whose factor product was switched to NovoEight found that although most felt they had little influence on the decision to switch, the majority continued to have confidence in the new treatment© Shutterstock

Figure 1

Participants’ perceived level of influence over the decision to switch product
Participants’ perceived level of influence over the decision to switch product

Figure 2

The proportion of patients who had to mix more than one vial of product before and after switching
The proportion of patients who had to mix more than one vial of product before and after switching

Figure 3

Participants’ views on packaging, user kits and ease of infusion compared with previous product
Participants’ views on packaging, user kits and ease of infusion compared with previous product

Figure 4

Participants’ rating views on NovoEight
Participants’ rating views on NovoEight

Comments on NovoEight offered by participants

POSITIVE COMMENTSNEUTRAL COMMENTSNEGATIVE COMMENTS
Packagingn=11Smaller boxes, ease of storingn=9n=13Two boxes, takes space
Ease of mixingn=8Easier to mix and administer
User kitsn=6Smaller, fewer resources wastedn=3Ordering ancillaries separately is inconvenient
Product overalln=3No bleeds, less painn=3Concerns about half-life

Statistical analyses based on those switching from ReFacto compared with other products (n=73/77)

Preparation timeShorterUnchangedGreaterP-value
ReFacto133460.0068
Non-ReFacto1270
Number of vialsFewerUnchangedMore
Refacto74510.055
Non-ReFacto7110
Trough levelsLowerUnchangedHigherNot tested/unknownP-value
ReFacto1267170.92
Non-ReFacto0937
ConfidenceBetterSameWorse
ReFacto64430.11
Non-ReFacto6122
Satisfaction rating12345
ReFacto121514210.020
Non-ReFacto002413
Packaging rating12345
ReFacto95179130.0073
Non-ReFacto015211

Patient characteristics

ALL PARTICIPANTS(N=77)ADULTS AGED 16+ YEARS(N=63)CAREGIVERS OF CHILDREN AGED <16 YEARS(N=14)
SeveritySevere (n=74)Moderate (n=1)Mild (n=2)Severe (n=60)Moderate (n=1)Mild (n=2)Severe (n=14)Moderate (n=0)Mild (n=0)
TreatmentOn demand (n=4)Prophylaxis (n=73)On demand (n=4)Prophylaxis (n=59)On demand (n=0)Prophylaxis (n=14)
Mean age at switch31.57 years11.14 years
Time on previous medication7.28 years7.28 years
Previous FVIII productReFacto (n=53)Helixate (n=10)Kogenate (n=5)Fanhdi (n=4)Optivate (n=1)unknown (n=4)ReFacto (n=43)Helixate (n=10)Kogenate (n=4)Fanhdi (n=4)Optivate (n=0)unknown (n=2)ReFacto (n=10)Helixate (n=0)Kogenate (n=1)Fanhdi (n=0)Optivate (n=1)unknown (n=2)
DOI: https://doi.org/10.17225/jhp00157 | Journal eISSN: 2055-3390
Journal RSS Feed
Language: English
Page range: 70 - 77
Published on: Jun 17, 2020
Published by: Haemnet Ltd
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
NovoEight,
switching treatment,
haemophilia,
patient experience,
people with haemophilia – views
Related subjects:
Medicine,
Basic medical science,
Basic medical science, other,
Clinical medicine,
Clinical medicine, other,
Pharmacy,
Pharmacology

© 2020 Debra Pollard, Kate Khair, Mike Holland, published by Haemnet Ltd
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 7 (2020): Issue 1 (January 2020)Next article